Eagle obtains 180 days marketing exclusivity for generic Vasostrict

Eagle Pharmaceuticals received 180 days of marketing exclusivity from the Food and Drug Administration for its recently approved generic version of Endo’s Vasostrict (vasopressin).
Levy

Eagle Pharmaceuticals has received 180 days of marketing exclusivity from the Food and Drug Administration for its recently approved generic version of Endo's Vasostrict (vasopressin).

Earlier in December, Eagle noted that Par, owned by Endo, had unilaterally withdrawn its bid to block the launch of generic alternative to Vasostrict through a court ruling.

[Read more: AAM report: Generics, biosimilars saved U.S. healthcare system $8B in 2020] 

Eagle added that in August, the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product did not infringe any of the patents Par asserted against the company.

Eagle's president and CEO Scott Tarriff said, "2022 will be an exciting period for us with our upcoming launch of vasopressin, as well as our launch of Pemfexy, beginning on Feb. 1, 2022.”

 

X
This ad will auto-close in 10 seconds